The acquisition bolsters WuXi's Laboratory Testing Division (LTD) in bioanalytical and DMPK/ADME services, particularly in studies of radio-labeled compounds, while gaining access to new agricultural and animal health customers. The resulting expansion and enhancement of WuXi's integrated service portfolio will accelerate the growth of LTD's business. This acquisition expands LTD's presence in North America, provides greater flexibility in service and support options for North American customers and presents the opportunity for further expansion.
XBL has 150 employees and operates a 45,000-square-foot research center in Plainsboro, N.J., and a 36,000-square-foot facility in Nanjing, China. The company is FDA- and USDA-registered, New Jersey-licensed for work with radioisotopes, USDEA-licensed for conducting research with Schedule 1-5 controlled substances and AAALAC-accredited.